Skip to main content
. 2019 Jan 29;13:900. doi: 10.3332/ecancer.2019.900

Table 2. Safety and AE with crizotinib.

Number (%)
Adverse event
• Visual Hallucination 01 (6.2%)
• Anaemia 02 (12.5%)
• Aspartate aminotransferase (AST)/alanine
aminotransferase (ALT)
03 (18.7%)
• Neutropenia 01 (6.2%)
• Diarrhoea 00
• QTc prolongation 02 (12.5%)
• Bradycardia 01 (6.2%)
• Renal insufficiency 02 (12.5%)
Drug interruptions
• Toxicity 01 (6.2%)
• Lack of compliance 02 (12.5%)
• Drug unrelated 00
Dose reductions 00